• Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: NaN
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.00
+0 (0.00%)
Get New Akorn Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AKRX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AKRX

Analyst Price Target is $0.00
This price target is based on 0 analysts offering 12 month price targets for Akorn in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a NaN upside from the last price of $0.00.

This chart shows the closing price for AKRX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Akorn. This rating has held steady since February 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/7/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/5/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/3/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/4/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/31/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/30/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/29/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/28/2020Royal Bank of CanadaLower TargetSector Perform$5.00 ➝ $2.00High
9/20/2019SunTrust BanksBoost TargetHold$3.50 ➝ $4.00High
8/12/2019Royal Bank of CanadaSet TargetHold$5.00Medium
5/30/2019Royal Bank of CanadaSet TargetHold$5.00Low
5/8/2019Royal Bank of CanadaBoost TargetSector Perform ➝ Reduce$5.00High
3/19/2019SunTrust BanksInitiated CoverageHold ➝ Hold$4.00Medium
3/1/2019Piper Jaffray CompaniesSet TargetBuy$8.00High
3/1/2019Royal Bank of CanadaSet TargetHold$4.00High
12/10/2018Piper Jaffray CompaniesSet TargetBuy$9.00Low
12/10/2018Royal Bank of CanadaSet TargetHold$6.00High
12/9/2018Craig HallumSet TargetBuy$11.00Low
11/27/2018Piper Jaffray CompaniesSet TargetBuy$9.00High
11/7/2018Royal Bank of CanadaSet TargetHold$9.00High
10/17/2018Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$5.00 ➝ $9.00High
10/4/2018Craig HallumUpgradeHold ➝ BuyLow
10/3/2018Jefferies Financial GroupLower TargetHold$6.00Low
10/2/2018Royal Bank of CanadaSet TargetHold$10.00High
10/2/2018Piper Jaffray CompaniesSet TargetHold$34.00 ➝ $5.00High
8/23/2018Deutsche Bank AktiengesellschaftReiterated RatingBuyHigh
7/25/2018Royal Bank of CanadaBoost TargetHold$25.00 ➝ $27.00Medium
4/30/2018Deutsche Bank AktiengesellschaftReiterated RatingHoldLow
4/23/2018Craig HallumLower TargetHold$34.00 ➝ $14.00High
4/23/2018Piper Jaffray CompaniesReiterated RatingHoldLow
4/12/2018Deutsche Bank AktiengesellschaftReiterated RatingHoldLow
3/29/2018Royal Bank of CanadaSet TargetHold$25.00Low
3/7/2018Piper Jaffray CompaniesSet TargetHold$34.00Low
3/1/2018William BlairReiterated RatingHoldHigh
2/22/2018Deutsche Bank AktiengesellschaftSet TargetHold$34.00High
(Data available from 1/29/2018 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
7/3/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/2/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/1/2022
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/1/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/31/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/30/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/30/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/29/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Akorn logo
Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.
Read More

Today's Range

Now: N/A

50 Day Range

MA: $0.19
Low: $0.09
High: $0.32

52 Week Range

Now: N/A

Volume

1,185,177 shs

Average Volume

9,601,876 shs

Market Capitalization

$3.60 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95

Frequently Asked Questions

What sell-side analysts currently cover shares of Akorn?

The following Wall Street sell-side analysts have issued reports on Akorn in the last year:
View the latest analyst ratings for AKRX.

What is the current price target for Akorn?

0 Wall Street analysts have set twelve-month price targets for Akorn in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Akorn in the next year.
View the latest price targets for AKRX.

What is the current consensus analyst rating for Akorn?

Akorn currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AKRX.

What other companies compete with Akorn?

How do I contact Akorn's investor relations team?

Akorn's physical mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company's listed phone number is 847-279-6100 and its investor relations email address is [email protected] The official website for Akorn is www.akorn.com. Learn More about contacing Akorn investor relations.